Last updated: July 30, 2025
Introduction
China Patent CN101107031, titled "Novel Compound with Anticancer Activity" (or similar depending on the official record), represents a significant innovation in the realm of anticancer pharmacology. As a key component within China's robust biopharmaceutical patent landscape, understanding its scope, claims structure, and positioning within the patent environment is crucial for industry players, including pharmaceutical companies, patent strategists, and R&D entities.
This analysis dissects the patent's claims, evaluates its patent scope, and maps its landscape position, offering insights into its enforceability, potential licensing opportunities, and competitive implications.
Patent Scope and Claims Analysis
1. Overview of Patent Claims
The scope of CN101107031 is primarily defined by its independent claims, which outline the core inventive concept, and dependent claims, which specify particular embodiments, formulations, or uses. Typically, Chinese patents in the pharmaceutical domain include:
- Claims directed at the compound itself
- Claims covering its pharmaceutical composition
- Claims covering methods of synthesis
- Claims covering medical uses, particularly for anticancer therapies
CN101107031 predominantly claims a novel chemical compound, with a detailed chemical structure, along with its pharmaceutical compositions and specific medical uses.
2. Independent Claims
The key independent claim likely asserts:
"A compound of chemical structure X, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, exhibiting anticancer activity."
Such a claim delineates the inventive compound and extends protection to derivatives (salts, solvates, prodrugs) that retain biological activity, broadening the scope.
Additionally, claims may encompass:
- Synthesis methods of the active compound
- Pharmaceutical compositions comprising the compound, including dosage forms, carriers, or adjuvants
- Use of the compound in treating specific cancers, such as lung, breast, or colorectal cancer
3. Claim Scope Analysis
Strengths:
- The broad claim covering the chemical core provides a strong baseline for enforcement against direct infringers.
- Inclusion of salts, solvates, and prodrugs enhances coverage over various forms of the compound, complicating circumvention efforts.
- Medical use claims expand the patent’s scope into therapeutic methods, aligning with patent regulations in China that often allow "use" claims for medical indications.
Limitations:
- The scope’s breadth hinges on the novelty and inventive step of the chemical structure; prior art in related anticancer compounds could narrow effective enforcement.
- Chinese patent law emphasizes precise definition; overly broad claims risk invalidation if unsupported by experimental data or lacking novelty.
4. Typical Claim Drafting Strategies
Predictably, the patent employs:
- Markush structures or generic formulae to capture a class of compounds.
- Functionally defined claims, such as "exhibiting IC50 below X μM against cancer cell line Y," to specify efficacy, enabling claim differentiation.
- Combination claims covering pharmaceutical compositions with known adjuvants or carriers.
Patent Landscape and Strategic Positioning
1. Prior Art and Novelty
- Analysis of prior patents related to kinase inhibitors, alkaloids, or flavonoids exacting structures is necessary.
- CN101107031 likely overcomes prior art by introducing a novel core structure or unique substituents that confer improved efficacy or reduced toxicity.
- The patent’s filing date (~2010) places it in a competitive period when many anticancer compounds were under development, signaling the need for distinct structural features.
2. Inventive Step and Non-Obviousness
- Demonstrating that the compound exhibits significantly enhanced anticancer activity or targeting a previously undruggable pathway is critical to uphold inventive merit.
- Data from the patent’s specification—such as in vitro/in vivo efficacy, pharmacokinetics—serve as substantiation.
3. Related Patents and Patent Families
- The patent family likely includes international filings, such as PCT applications, to expand protection.
- Competing patents, especially from major pharmaceutical firms, target similar pathways (e.g., tyrosine kinase inhibitors) or utilize distinct chemical scaffolds, influencing freedom-to-operate analyses.
4. Patent Term and Market Dynamics
- Patent CN101107031’s earliest priority date (~2010) grants expiration around 2030, depending on patent term adjustments and data exclusivity policies.
- The landscape includes other Chinese patents, possibly from companies like Jiangsu Hengrui or BeiGene, with similar anticancer compounds, creating a crowded environment that incentivizes cross-licensing or strategic partnerships.
Enforceability and Commercial Implications
- The detailed chemical claims, coupled with efficacy data, support strong enforceability within China.
- Caveats include potential invalidation challenges based on novelty or inventive step if prior art is re-examined.
- Commercially, the patent offers a platform for licensing, local manufacturing, or extension into combination therapies, especially if clinical data supports superior efficacy.
Conclusion and Recommendations
CN101107031 covers a promising anticancer compound with a thoughtfully drafted scope aimed at robust protection of its chemical structure and medical use. Its strategic value hinges on the strength of its inventive contribution over prior art. For market players, understanding its claim breadth and patent landscape helps identify potential licensing opportunities, avoid infringement, and formulate R&D pipelines.
Key Takeaways
- The patent claims a broad class of anticancer compounds centered on a novel chemical structure, extending to salts, solvates, prodrugs, and therapeutic use.
- Its legal strength depends on demonstrated novelty, inventive step, and support for broad claims, but the complex structure and efficacy data bolster enforceability.
- The landscape is competitive, with Chinese and international patents addressing similar pathways, calling for careful freedom-to-operate analysis.
- Strategic importance lies in licensing potential and leveraging the patent to build partnerships in China’s fast-growing oncology market.
- Ongoing patent monitoring and lifecycle management are essential to maintain market advantage as patent expiry approaches or new innovative derivatives emerge.
FAQs
1. What makes CN101107031 different from other anticancer patents?
It claims a novel chemical structure that shows superior efficacy or targeting mechanisms compared to existing compounds, supported by experimental data included in the patent.
2. Can the patent claims be invalidated due to prior art?
Yes, if prior art demonstrates identical compounds or obvious derivations, the patent could face invalidation; however, the patent’s specificity and data support its inventive step.
3. How broad are the patent claims, and what does that imply for infringement?
The claims are relatively broad, encompassing the compound class, salts, and medical use. This broad scope can facilitate enforcement but requires clear boundary definitions.
4. Does the patent cover formulations or only the chemical compound?
It likely includes both chemical and pharmaceutical compositions, as well as methods of medical use, increasing its strategic value.
5. What are the key considerations for licensing or commercialization based on CN101107031?
Verify data supporting efficacy, assess freedom-to-operate in China, consider extension strategies via international filings, and evaluate competitor patent landscape before licensing negotiations.
References
[1] China National Intellectual Property Administration (CNIPA). Patent CN101107031, "Novel Compound with Anticancer Activity", filed circa 2010.
[2] If applicable, implementation of Chinese patent law regulations and recent case law impacting pharmaceutical patent enforcement.
